Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

IN THE CLAIMS

Claim 1 (Currently amended).   A method for treating cognitive dysfunction of a patient associated with low LDL-cholesterol values in serum, other than one ~~diagnosed as suffering from~~ being treated for Alzheimer's disease, by modulating nicotinic receptors, said method comprising determining the LDL-cholesterol value for such patient and administering an effective amount of a nicotinic allosteric potentiator ~~a nicotinic agonist or a mixture thereof~~ to a patient other than one ~~diagnosed as suffering from~~ being treated for Alzheimer's Disease with a nicotinic allosteric potentiator who has been determined to have a serum–LDL-cholesterol level of below 109 mg/dl.

Claim 2 (canceled).

Claim 3 (Previously Presented).   A method as claimed in claim 1 wherein said low cholesterol values are the result of treatment with HMG-CoA reductase inhibitors.

Claim 4 (Previously Presented).   A method as claimed in claim 1 wherein said modulation of nicotinic receptors is effected by administering an effective amount of a galanthamine or lycoramine analog to a patient in need of such modulation.

Claim 5 (Withdrawn).   A method as claimed in claim 2 wherein said modulation of nicotinic receptors is effected by administering an effective amount of a galanthamine or lycoramine analog to a patient in need of such modulation.

Claim 6 (Withdrawn).   A method as claimed in claim 3 wherein said modulation of nicotinic receptors is effected by administering an effective amount of a galanthamine or lycoramine analog to a patient in need of such modulation.